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Background: Mutations in the gene for alpha-galactosidase A result in Fabry disease, a rare, X-linked lysosomal
storage disorder characterized by a loss of alpha-galactosidase A enzymatic activity. The resultant accumulation of
glycosphingolipids throughout the body leads to widespread vasculopathy with particular detriment to the kidneys,
heart and nervous system. Disruption in the autophagy-lysosome pathway has been documented previously in
Fabry disease but its relative contribution to nervous system pathology in Fabry disease is unknown. Using an
experimental mouse model of Fabry disease, alpha-galactosidase A deficiency, we examined brain pathology in
20-24 month old mice with particular emphasis on the autophagy-lysosome pathway.
Results: Alpha-galactosidase A-deficient mouse brains exhibited enhanced punctate perinuclear immunoreactivity
for the autophagy marker microtubule-associated protein light-chain 3 (LC3) in the parenchyma of several brain
regions, as well as enhanced parenchymal and vascular immunoreactivity for lysosome-associated membrane
protein-1 (LAMP-1). Ultrastructural analysis revealed endothelial cell inclusions with electron densities and a pronounced
accumulation of electron-dense lipopigment. The pons of alpha-galactosidase A-deficient mice in particular exhibited
a striking neuropathological phenotype, including the presence of large, swollen axonal spheroids indicating axonal
degeneration, in addition to large interstitial aggregates positive for phosphorylated alpha-synuclein that co-localized
with the axonal spheroids. Double-label immunofluorescence revealed co-localization of phosphorylated alpha-synuclein
aggregates with ubiquitin and LC3.
Conclusion: Together these findings indicate widespread neuropathology and focused axonal neurodegeneration in
alpha-galactosidase A-deficient mouse brain in association with disruption of the autophagy-lysosome pathway, and
provide the basis for future mechanistic assessment of the contribution of the autophagy-lysosome pathway to this
histologic phenotype.
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Electron microscopyBackground
Alpha-Galactosidase A (α-Gal A) is a soluble lysosomal
enzyme that hydrolyzes the terminal alpha-galactosyl moi-
ety from glycolipids and glycoproteins. The predominant
lipid hydrolyzed by α-Gal A is ceramide trihexoside, also
known as globotriaosylceramide or Gb3 [1]. Mutations in* Correspondence: shacka@uab.edu
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unless otherwise stated.the α-Gal A gene (GLA) occur in the rare, X-linked lyso-
somal storage disorder called Fabry disease, and resultant
decreases in α-Gal A enzymatic activity lead to the pro-
gressive and widespread accumulation of glycosphingoli-
pids in most bodily tissues and fluids including Gb3 and
globotriaosylsphingosine (also known as lyso-Gb3) [1,2].
The prominent effects of α-Gal A deficiency and glyco-
sphingolipid accumulation on the vascular endothelium
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tions to the kidneys, heart and brain (reviewed in [3]).
There are widespread central and peripheral nervous
system manifestations of Fabry disease. Peripheral ner-
vous system involvement includes small fiber neuropathy
that is associated with neuropathic pain and autonomic
dysfunction (reviewed in [4,5]). Central nervous system
involvement in Fabry disease is associated primarily with
cerebrovascular dysfunction that contributes to a variety
of neurological deficits ([6], reviewed in [5]). Prominent
alterations in cerebral blood vessels, including stenosis
of small vessels and enlargement of large vessels may
occur either primary to glycosphingolipid accumulation
or secondary to unresolved downstream signaling mech-
anisms and contribute to an increased risk and incidence
for stroke in Fabry patients, in particular those that in-
volve the vertebrobasilar system [6,7]. White matter le-
sions are also common neuropathological findings, in
addition to neuronal swelling, axonal degeneration and
accumulation of ceroid lipofuscin [8-10].
The autophagy-lysosome pathway (ALP) is an import-
ant signaling pathway that maintains intracellular energy
balance and in turn affects cell survival [11,12]. Disrup-
tion of the ALP is a common hallmark of lysosomal stor-
age diseases and several have documented alterations in
the nervous system, which may contribute in part to the
onset and progression of nervous system pathophysi-
ology [13]. Disruption in the ALP has been documented
previously in biopsies of Fabry disease patient muscle
and kidney and in vitro in fibroblasts/lymphoblasts cul-
tured from Fabry patients [14,15]. However, whether the
ALP is altered in Fabry disease brain has not been previ-
ously documented.
We have examined the CNS neuropathology resulting
from α-Gal A deficiency by comparing brains from α-Gal
A deficient vs. wild-type mice, using a well-established
mouse model of Fabry disease with previous documented
peripheral nervous system findings similar to those de-
scribed in humans with Fabry disease [16-21]. We report
widespread alterations of ALP-associated markers through-
out the brains of α-Gal A-deficient mice. Such alterations
are associated with vascular and parenchymal pathology as
well as hindbrain axonal neurodegeneration, together sug-
gesting that the ALP may play an important role in the de-
velopment of CNS pathophysiology in Fabry disease.
Methods
Fabry disease mouse model
The α-Gal A gene-disrupted mouse, generated by inser-
tion of a neo cassette in Exon 3 of the mouse Gla gene,
lack α-Gal A enzymatic activity but otherwise live a nor-
mal lifespan [18]. Breeding pairs were obtained initially
from the National Institutes of Health (Bethesda, MD)
and in our colony were raised on a C57BL/6 background.Heterozygous (HET) females were bred with control males
to maintain the mouse colony. Mutant male–female ma-
tings were performed to generate litters containing α-Gal A
deficient mice for these studies. Mice were genotyped using
the following primers: Gla-forward: 5′-ACTGGTATCCT
GGCTCTATCC-3′; Gla-reverse: 5′-GATCTACGCCCCA
GTCAGCAAATG-3′; Neo-reverse: 5′-TCCATCTGCAC
GAGACTAGT-3′, to indicate either a 550 bp product for
control mice, or a 750 bp PCR product for α-Gal A de-
ficient mice. Control C57BL/6 wild-type mice matched
for age and strain were purchased from Charles River
Laboratories, in association with the National Institute
on Aging. Twenty- to 24-month-old C57BL/6 wild-
type (+/o) and α-Gal A-deficient (−/0) male mice were
used for this study. With the exception of electron
microscopic analysis (n = 1 wild-type and α-Gal A-
deficient mouse), results from all experiments were
performed using male mice from at least three inde-
pendent litters. “All animal experimentation con-
formed to UAB IACUC standards and Principles of
laboratory animal care” (NIH publication No. 86–23,
revised 1985) were followed.
Specimen preparation
Mice were euthanized by exsanguination under isofluor-
ane anesthesia, followed by trans-cardiac perfusion with
PBS. Brains from perfused mice were removed, cut sagit-
tally along the midline, and post-fixed in either 4% para-
formaldehyde or Bouin’s fixative solution (71.5% saturated
picric acid solution, 23.8% of a 37% w/v formaldehyde
solution, 4.7% glacial acetic acid) for 48 hours at 4°C,
followed by transfer to 70% EtOH. Hemi-brains were then
processed and subsequently embedded in paraffin blocks
and stored before sectioning.
Paraffin blocks were cooled on ice, cut on a Microm
HM355S rotary microtome (Thermo Fisher Scientific,
Waltham, MA) at a thickness of 6 μm, applied to Super-
frost® Plus glass slides (12-550-15, Thermo Fisher Scien-
tific, Waltham, MA), and baked overnight at 50°C. Before
staining, the slides were deparaffinized in changes of
CitriSolv® (22-143-975, Thermo Fisher Scientific, Waltham,
MA) and 70% isopropanol. Antigen retrieval was accom-
plished by incubating in sodium citrate buffer (1.8% 0.1 M
citric acid, 8.2% 0.1 M sodium citrate, in distilled water,
pH 6.0) in a rice cooker for 30 minutes. The slides were
blocked with PBS blocking buffer (1% BSA, 0.2% non-fat
dry milk, and 0.3% Triton-X-100 in PBS) for 30 minutes,
and treated with the appropriate primary antibodies di-
luted in blocking buffer overnight at 4°C. This was
followed by incubation with secondary antibodies di-
luted in blocking buffer for 1 h at room temperature.
The slides were then processed according to the follow-
ing fluorescence or chromogenic IHC methods in prep-
aration for imaging.
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Autophagosomes were labeled with a rabbit polyclonal
antibody raised against mouse microtubule-associated
protein light chain 3, or LC3 (Sigma, L7543, diluted
1:50,000). Lysosomes were labeled using rat-anti-mouse
lysosome-associated membrane protein-1 (LAMP-1,
University of Iowa Hybridoma Bank, clone 1D4B-s,
diluted 1:2,000). Alpha-synuclein phosphorylated at serine-
129 was labeled using rabbit-anti-mouse phosphorylated-α-
synuclein (Abcam, ab168381, diluted 1:6,000). Ubiquitin
was labeled using mouse-anti-bovine ubiquitin (Clone 6C1,
Sigma, U 0508, diluted 1:10,000), a generous gift of Dr.
Scott Wilson (UAB). Neuronal nuclei were labeled using
mouse-anti-NeuN (Millipore, MAB377B, 1:5000). Second-
ary antibodies used were SuperPicture™ anti-rabbit poly-
meric antibody (Invitrogen, 87–9263, diluted 1:10) and
ImmPress™ anti-mouse polymeric antibody (Vector Labora-
tories, MP-7402, diluted 1:50). Vascular endothelial cell sur-
face labeling was done with fluorescein-tagged potato lectin
(FPL, Vector Labs, FL-1161, diluted 1:1,000), obtained as a
generous gift of Dr. Inga Kadisha (University of Alabama at
Birmingham). Tyramide signal amplification (TSA) was
used for detection. For fluorescence immunohistochemistry
(IHC), TSA Plus-Cy3 (Perkin Elmer, NEL744E001KT) and
TSA Plus-FITC (Perkin Elmer, NEL741001KT) were
used. For chromogenic staining, biotin tyramide (Perkin
Elmer, SAT700001EA) and avidin biotin complex reagent
(ABC, Pierce, 32020), were used followed by development
with 3,3′-diaminobenzidine tetrahydrochloride (DAB)
substrate (Pierce, Rockford, IL), and nuclear counterstain
with hematoxylin.Fluorescence IHC
Slides labeled for LC3, LAMP-1, and phosphorylated-α-
synuclein antibodies intended for fluorescence were incu-
bated in TSA Plus-Cy3 (diluted 1:1,500 in TSA amplification
diluent) for 30 minutes at room temperature, and
ubiquitin-labeled slides were incubated in TSA Plus-FITC
(diluted 1:500 in TSA amplification diluent). For double
labeling, slides were treated with hydrogen peroxide to
block unused and endogenous peroxidases and blocked
again before adding the second primary antibodies. All
slides were counterstained with bis-benzimide (Sigma) nu-
clear stain (0.2ug/ml in PBS) for 10 minutes and mounted
with Fluoromount G (SouthernBiotech, 0100–01) and
1.5 mm glass coverslips.Chromogenic IHC
Slides labeled with phosphorylated α-synuclein were in-
cubated with biotin tyramide conjugate (diluted 1:400 in
amplification diluent) for 10 minutes followed by ABC
for 30 minutes. The slides were then developed using
DAB peroxidase substrate for 10 minutes and quenchedin water. After hematoxylin counterstain, the slides were
mounted, coverslipped, and stored before imaging.
Electron microscopy
Small mm2 sections of brain tissue were incubated over-
night in “Half-Karnovsky’s fixative” (2% glutaraldehyde,
2.5% paraformaldehyde in 0.1 M cacodylate buffer with
2 mM Ca++ and 4 mM Mg++). Following fixation and in-
cluding rinses between steps, the tissue was post-fixed with
1% osmium tetroxide in 0.1 M calcium carbonate buffer,
dehydrated in an ethanol series up to 100% followed by 3
steps in propylene oxide. Finally the tissue was infiltrated
and embedded over 2 days in EPON-812 epoxy resin.
Sections were cut on a Reichert-Jung Ultracut-S ultra-
microtome, stained with uranyl acetate and lead citrate.
Imaging
Fluorescence imaging was performed on the Zeiss LSM
700 Confocal Microscope Platform (Carl Zeiss GmbH,
Jena, Germany) or the Nikon A1 Confocal Microscope
System (Nikon Instruments Inc., Melville, NY). Chromo-
genic imaging was performed on a Zeiss Axioskop
microscope and captured using Zeiss Axiovision® soft-
ware (Carl Zeiss GmbH, Jena, Germany). Ultrastructural
images were obtained on the FEI Tecnai T12 Spirit trans-
mission electron microscope at 80 kV (FEI, Hillsboro, OR)
in the UAB High Resolution Imaging Facility. All images
were subsequently processed in Adobe Photoshop® for
presentation.
Image and statistical analysis
Quantitative analysis of images was performed using
ImageJ (National Institutes of Health, Bethesda, MD).
Counting of phosphorylated α-synuclein aggregates and
axonal spheroids was performed using the “cell counter”
plugin. Phosphorylated-α-synuclein aggregates were con-
sidered if they exceeded 10 microns in diameter. Single
label mean fluorescence intensity analysis for LC3 was per-
formed using the “measure” command on background-
subtracted images and recording the mean value. Co-
localization analysis for phosphorylated α-synuclein
with either LC3 or ubiquitin was performed using the
“Coloc 2” plugin; the Costes p-value and thresholded
Manders values were recorded as previously described
[22]. Briefly, the Costes p-value is an indicator of the ex-
istence of co-localization within the field or region of
interest. Threshold calculation accounts for background
noise in each channel. The thresholded Manders ana-
lysis compares two color channels (probes) and provides
a channel-specific measure of the number of pixels
above threshold in one channel colocalizing with those
in the other with a numerical range of 0 to 1, with 1 being
complete co-localization. All co-localization analyses were
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fields from an n of 4 mice.
Statistical analysis for LC3 mean fluorescence intensity
was performed using GraphPad Prism (GraphPad Soft-
ware Inc., La Jolla, CA) and significance was determined
at p < 0.05 using the Student’s t-test.Results
Immunoreactivity of autophagy marker LC3 is increased
throughout the brains of α-galactosidase A-deficient mice
As α-Gal A deficiency is known to disrupt the ALP in
skeletal and cardiac muscle and kidneys of patients with
Fabry disease, we determined the extent to which the
ALP is altered in the CNS by assessing brains of α-Gal
A-deficient versus wild-type mice as a correlate to hu-
man CNS pathology [14,15]. As a correlate to the age-
dependent progression of Fabry disease, brain sections
from aged (20-24-month-old) mice were probed with
an antibody against microtubule-associated protein
light-chain 3 (MAP-LC3 or LC3) to identify autopha-
gosomes (Figure 1). In general, LC3 immunoreactivity
was markedly higher throughout the gray matter of
brains of α-Gal A-deficient mice (−/0) compared to
those of age-matched wild-type control mice (+/0).
Results in Figure 1 illustrate this relative increase in
four distinct brain regions: the cerebellum (Figure 1a-f),
pons (Figure 1h-m), hippocampus (Figure 1o-t) and
cortex (Figure 1u-z). Quantification of the significant
relative increase in mean fluorescence intensity of LC3
in the cerebellum and pons is shown in Figure 1g and
Figure 1n, respectively.
Increases in cerebellar LC3 immunoreactivity were
most striking in Purkinje cells from α-Gal A-deficient
mice. The inset in Figure 1f highlights the punctate na-
ture of LC3 staining, suggesting either the formation of
LC3-positive autophagosomes or the accumulation of
LC3-positive autophagic material. This inset is represen-
tative, as similar punctate staining patterns were noted
throughout the areas surveyed. Enhanced LC3 immuno-
reactivity was also observed in the cerebellar molecular
layer of α-Gal A-deficient (Figure 1d) versus wild-type
(Figure 1a) mice. Increased LC3 immunoreactivity in α-
Gal A-deficient mice was observed in dorsal and lateral
aspects of the pons. Enhanced LC3 immunoreactivity
in the hippocampus is illustrated in the dentate gyrus
(Figure 1r), although increased immunoreactivity was
observed in other sub-regions including the Cornu
Ammonis (CA) regions (data not shown). Enhanced
LC3 immunoreactivity was most apparent in layer 2 of
the cortex from α-Gal A-deficient mice (Figure 1x),
with minimal staining in layer 1 (data not shown). The
area of the cortex depicted in Figure 1 (panels u-z) is
from layer 2 of the somatomotor area.LAMP-1 immunoreactivity is markedly increased in both
parenchymal and vascular regions of α-gal A-deficient
mouse brain
Increased levels of the lysosome marker LAMP-1 (lyso-
some-associated membrane protein-1) often accompany
increases in LC3 in models of lysosomal storage diseases
or models of induced lysosome dysfunction and suggest
a compromise in autophagy completion [23-25]. To as-
sess LAMP-1 immunoreactivity in α-Gal A-deficient
mouse brain we first performed chromogenic detection
(Figure 2). Consistent increases in LAMP-1 immunore-
activity were observed throughout the brains of α-Gal
A-deficient versus wild-type mice, including but not lim-
ited to the cerebellum (Figure 2a, e, i), pons (Figure 2b,
f, j), hippocampus (Figure 2c, g, k) and cortex (Figure 2d,
h, l). Enhanced LAMP-1 immunoreactivity was localized
to both perinuclear regions and neuritic processes in the
parenchyma (arrowheads) in addition to an apparent
vascular association with blood vessels (arrows). High
magnification insets (Figure 2i-l) show in detail the peri-
nuclear and neuritic staining patterns. To determine
whether the increase in vascular LAMP-1 immunoreac-
tivity in the brains of α-Gal A deficient mice was also lo-
calized to endothelial cells, brain sections were also
double-labeled with an anti-LAMP-1 antibody and fluor-
escent potato lectin (FPL) (Figure 3), a fluorescein-
tagged lectin that binds to cell-surface receptors on vas-
cular endothelial cells [26]. There was no discernible dif-
ference detected in endothelial cell staining by FPL in α-
Gal A deficient vs. wild-type mouse brain (indicated by
green arrowheads in cerebellum, Figure 3b, f ). However,
enhanced LAMP-1 immunoreactivity in α-Gal A defi-
cient mouse brains (indicated by red arrowheads in cere-
bellum, Figure 3a, e) co-localized remarkably with FPL
labeling of endothelial cell surfaces (arrows, Figure 3h, p,
x, ff ).
Ultrastructural analysis of α-galactosidase A-deficient
mouse brain reveals accumulation of inclusions and
lipopigment
As a correlate to our IHC results, we analyzed sections
from the cerebellum and cortex of a 24 mo α-Gal A-
deficient and wild-type mouse by electron microscopy to
identify any ultrastructural abnormalities known to be
associated with ALP deficiency [14]. Wild-type mice ex-
hibited normal-appearing vasculature (Figure 4a) and
parenchyma (Figure 4b) in the cerebellum and normal
nuclei and cytoplasm in cortical neurons (Figure 4c).
Representative images from α-Gal A-deficient mouse
brain indicate a prominent electron-dense inclusion in
the cytoplasm of a cerebellar endothelial cell that con-
tains electron densities (Figure 4d, inset Figure 4g), and
the presence of both cerebellar (Figure 4e, h) and cor-
tical (Figure 4f, i) electron-dense osmiophilic inclusions
Figure 1 (See legend on next page.)
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Figure 1 LC3 levels are enhanced throughout α-Gal A-deficient mouse brain. Sagittal brain sections from male 20- to 24-month-old α-Gal
A +/0 (a-c, h-j, o-q, u-w) or -/0 (d-f, k-m, r-t, x-z) mice were immunolabeled with an antibody against LC3 (a, d, h, k, o, r, u, x) and counterstained
with bis-benzimide (b, e, i, l, p, s, v, y). Inset in panel f indicates LC3-positive puncta. The images shown were taken from the cerebellum (CB), pons
(PONS), hippocampus (HIP), and cortex (CTX). Scale bars = 50 microns. Graphs in (g and n) show relative mean fluorescence intensity of LC3 signal
normalized to averaged α-Gal A +/0 levels (n = 3) (*p < 0.05, Student’s t-test).
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We did not appreciate any accumulation of autophago-
somes in α-Gal A-deficient mouse brain, suggesting that
the increase in LC3 immunoreactivity observed by IHC
in Figure 1 may be localized to lipid-containing aggre-
gates of undigested autophagic substrate.
Enhanced immunoreactivity for phosphorylated alpha-
synuclein in α-gal A-deficient mouse brain is localized to
areas of axonal degeneration
Alpha-synuclein is an ALP substrate and its aberrant accu-
mulation has been previously documented following the
pharmacological disruption of the ALP as well as in mouse
models of lysosomal storage diseases with known ALP dys-
function [24,27-31]. As the phosphorylated form of α-
synuclein is closely associated with the neuropathogenesis
of disease, we examined its distribution in the brains of α-
Gal A-deficient mice (Figure 5) [32-34]. Immunohisto-
chemical analysis for phosphorylated-α-synuclein revealed
a noticeable accumulation of large interstitial aggregates
of immunoreactivity localized to the pons white matter in
α-Gal A-deficient mouse brain (Figure 5c, inset with arrow-
heads, Figure 5d). Immunoreactivity for phosphorylated-α-
synuclein in the wild-type pons was less remarkable with
the appearance of aggregates that were much smaller in size
(Figure 5a, b). Quantification of aggregates in sections of a-
Gal A deficient pons revealed an average of five per field
that were greater than 10 microns in diameter (Figure 5e).
Analysis of multiple sections from wild-type pons revealed
a complete absence of these larger diameter aggregates.
Perinuclear immunoreactivity of equal intensity was also
observed for phosphorylated-α-synuclein in brains of wild-
type and α-Gal A-deficient mice, as represented by images
captured from the dentate gyrus sub-region of the hippo-
campus (Figure 5f, g). Further investigation of pontine
neuropathology in α-Gal A-deficient mice by hematoxylin
and eosin (H&E) analysis revealed the consistent ap-
pearance of large, swollen, eosinophilic axonal spheroids
(Figure 6b, arrows) that indicate axonal degeneration
and which are absent in wild-type mice (Figure 6a). Both
observations are quantified in Figure 6c. In addition,
histochemical analysis of the pons from serial sections
of α-Gal A-deficient mouse brain indicated appro-
ximately 65 percent (Figure 6f) of areas of enhanced
phosphorylated-α-synuclein immunoreactivity (arrows,
Figure 6e) were within and adjacent to eosinophilic axonal
spheroids (arrows, Figure 6d).As insoluble α-synuclein-containing aggregates are
often associated with ubiquitin, we next performed double-
label immunofluorescence analysis of phosphorylated-α-
synuclein and ubiquitin (Figure 7a-h) to determine their
relative degree of co-localization [34,35]. In general, immu-
noreactivity for ubiquitin was noticeably greater in α-Gal
A-deficient versus wild-type brain, as demonstrated in the
pons by a relative enhancement of immunoreactive aggre-
gate species (green arrowheads, Figure 7b, f), and para-
lleled increases in phosphorylated-α-synuclein observed in
α-Gal A-deficient versus wild-type pons (red arrowheads,
Figure 7a, e). Analysis of the merged images indicated that
in α-Gal A-deficient pons, phosphorylated-α-synuclein
aggregates were ubiquitin-positive (Figure 7h), whereas
in the wild-type pons ubiquitin-positive aggregates
were not immunoreactive for phosphorylated-α-synuclein
(Figure 7d). Co-localization analysis of phosphorylated-α-
synuclein and ubiquitin signals demonstrated co-localization
to be both significant (Costes value of 1.0) and meaningful
(tM1 = 0.506, tM2 = 0.856), such that 86% of pixels indi-
cating phosphorylated-α-synuclein co-localized with those
indicating ubiquitin.
It has been demonstrated previously that the disruption
of the ALP contributes to axonal degeneration (reviewed in
[36]). Thus double-label immunofluorescence was also per-
formed to determine if phosphorylated-α-synuclein aggre-
gates with spheroid-like morphology in the pons of α-Gal
A-deficient mice co-localized with the autophagy marker
LC3 (Figure 7i-l). LC3 immunoreactivity appeared in struc-
tures morphologically resembling axonal spheroids (red ar-
rowheads, Figure 7j) and exhibited co-localization with
phosphorylated-α-synuclein (Figure 7l), providing evi-
dence that α-Gal A deficiency-induced axonal degeneration
involves, in part, disruption of the ALP. Co-localization
analysis of LC3 and phosphorylated-α-synuclein signals
demonstrated co-localization to be both significant (Costes
value of 0.958) and meaningful (tM1 = 0.499, tM2 = 0.765),
where about 77% of pixels indicating LC3 co-localized with
those containing phosphorylated-α-synuclein.
Changes observed in α-gal A deficient mice are not
associated with neuron loss
To address the possibility that autophagic and neuropatho-
logical changes observed in α-Gal A deficient mouse brain
may be associated with changes with global changes in
neuron density, we stained sections with an antibody against
neuronal nuclei (NeuN) and counted positively-stained cells
Figure 2 Evidence of enhanced neuritic and perinuclear LAMP-1 levels. Sagittal brain sections from male 20- to 24-month-old α-Gal A +/0
(a-d) or -/0 (e-h)mice were immunolabeled with an antibody against LAMP-1 and nuclei were counterstained with hematoxylin. Higher magnification
areas of interest from α-Gal A -/0 sections are included for detail (i-l). Arrowheads indicate areas of increased perinuclear (f, j) and neuritic (e, g, h, I, k, l)
LAMP-1 immunoreactivity, while arrows indicate vascular LAMP-1 staining. The images shown were taken from the cerebellum, pons, hippocampus,
and cortex as indicated. Scale bars = 50 microns.
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pus, and pons) from α-Gal A +/0 (Additional file 1: Figure
S1a-c) and α-Gal A -/0 (Additional file 1: Figure S1d-f)
mouse brains (n = 3). Significant differences in numbers
of NeuN positive neurons were not observed between
α-Gal A +/0 and α-Gal A -/0 mouse brains (Additional
file 1: Figure S1g).
Discussion
Although α-Gal A deficiency has long been associated
with nervous system dysfunction, a connection between
central nervous system involvement and defects in the
ALP has yet to be established in Fabry disease. We re-
port widespread alterations of ALP-associated markers
throughout the brains of α-Gal A-deficient mice. LC3, a
marker of autophagic vacuoles, was substantially increased
in multiple brain regions in connection with α-Gal A defi-
ciency (Figure 1). LAMP-1, a marker of intact lysosomeswas likewise increased throughout α-Gal A-deficient
mouse brain, not only in neurons and neuritic processes,
but also in vascular endothelial cells (Figures 2 and 3). Ul-
trastructural analysis revealed lipopigment-containing in-
clusions suggesting the accumulation of ALP byproduct
(Figure 4). We also demonstrated the presence of large ag-
gregate lesions of phosphorylated α-synuclein in the α-Gal
A-deficient pons (Figure 5), which further co-localized
with large axonal spheroids (Figure 6). Finally, we showed
that α-synuclein-containing lesions in the pons also co-
localized with ubiquitin and containing and LC3 (Figure 7).
The present work thus illuminates a novel connection
between distinct neuropathology and neurodegenera-
tion (e.g. axonal spheroids) and alterations in the ALP,
in a mouse model of α-Gal A deficiency.
Increased levels of ALP-associated markers clearly
support a role for its disruption in the CNS of α-Gal A-
deficient mice. Such increases would be predicted to
Figure 3 (See legend on next page.)
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Figure 3 LAMP-1 levels are enhanced throughout α-Gal A-deficient brain and exhibit vascular localization. Sagittal brain sections from
male 20- to 24-month-old α-Gal A +/0 (a-d, i-l, q-t, y-bb) or -/0 (e-h, m-p, u-x, cc-ff) mice were immunolabeled with an antibody against
LAMP-1 (a, e, i, m, q, u, y, cc), and fluorescent potato lectin (b, f, j, n, r, v, z, dd) and counterstained with bisbenzimide (c, g, k, o, s, w, aa, ee).
Red arrowheads (a, e) indicate areas of intense vascular LAMP-1 immuoreactivity and green arrowheads (b, f) indicate vascular staining in similar
locations. White arrows (d, h, p, x, ff) indicate the preferential localization of LAMP-1-positive staining to the vascular endothelium. The images shown
were taken from the cerebellum (CB), pons (PONS), hippocampus (HIP), and cortex (CTX) as indicated. Scale bars = 50 microns.
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ary to lysosome dysfunction, a common feature of other
lysosomal storage diseases [13,23,25,37,38]. In support of
this argument, previous investigation of Fabry disease kid-
ney, and cultured fibroblast/lymphoblasts from Fabry dis-
ease patients suggest that α-Gal A deficiency affects the
ALP by inhibiting macroautophagy completion [14]. While
our IHC results indicate increased punctate LC3 immuno-
reactivity (Figure 1), a relative lack of autophagosomes was
observed by electron microscopic analysis (Figure 4). A
possible explanation for this discrepancy may be the
localization of LC3 with ceroid lipofuscin (Figure 4),Figure 4 Representative ultrastructural analysis of α-Gal A-deficient a
(CB; panels a, b, d, e, g, h) and cortex (CTX; panels c, f, i) of 21 month-old
(+/0; panels a-c) mice were prepared for electron microscopic analysis. Brain u
blood vessels (panel a) and perikarya (panel b) and neuronal cells with norm
a blood vessel in α-Gal A -/0 cerebellum contains a prominent inclusion (p
(arrowheads). In both cerebellum (panel e; panel h represents inset box) a
numerous lipopigment aggregates consisting of lipid droplets associatedconsidered to be an accumulation of autophagic mate-
rial that is unable to be effectively degraded [37,39].
However, recent in vitro analyses of α-Gal A deficiency
indicated an increase in basal levels of LC3-II, the iso-
form of LC3 that is associated with double-membraned
autophagosomes [23,40], resulting possibly from aberrant
autophagy induction [41]. Other studies have shown en-
hanced LC3 immunoreactivity in the absence of detectable
autophagosomes, such as one describing VPS34 deficiency
in cardiomyocytes [42], and another describing LC3-II
localization to lipid droplets rather than autophagosomes
[43]. As the availability of tissues for the present study wasnd wild-type mouse brain. Ultra-thin sections of the cerebellum
α-Gal A hemizygous (−/0; panels d-i) and α-Gal A wild-type
ltrastructure from the α-Gal A +/0 mouse exhibited normal appearing
al appearing nuclei and cytoplasm (panel c). The endothelial cell lining
anel d; panel g represents inset box) exhibiting electron densities
nd cortex (panel f; panel i represents inset box) there appeared
with electron-dense osmiophilic material. Scale bars = 500 nm.
Figure 5 Aggregates immunopositive for phosphorylated α-synuclein in the pons of α-Gal A-deficient brain. Sagittal brain sections from
male 20- to 24-month-old α-Gal A +/0 (a, b, f) or -/0 (c, d, g) mice were immunolabeled with an antibody against phosphorylated α-synuclein.
Panels a-d show similar regions within the pons, and (b and d) are 8x magnifications of the boxes in (a and c). Black arrowheads indicate areas
of intense phosphorylated α-synuclein immunoreactivity (d). Phosphorylated-α-synuclein aggregates above 10 microns in diameter were counted
per field and graphed in panel e, which shows that none were present in α-Gal A +/0 pons while α-Gal A -/0 pons demonstrated an average of
approximately 5 aggregates per field. Panels (f and g) show similar perinuclear phosphorylated α-synuclein staining patterns in the hippocampus
between α-gal A +/0 (f) and -/0 (g) brains. Scale bars = 100 microns (a-d), 50 microns (f, g).
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Figure 6 Phosphorylated α-synuclein aggregates localized to axonal spheroids specific to the α-Gal A-deficient brain. Sagittal brain
sections from male 20- to 24-month-old α-Gal A +/0 (a) or -/0 (b) mice were stained with hematoxylin and eosin and serial sections from α-Gal
A -/0 mice in the same group were stained with either hematoxylin and eosin (d) or an antibody against phosphorylated α-synuclein (e).
H&E staining indicates large eosinophilic axonal spheroids in α-gal A -/0 brains (white arrows, b) that are not evident in α-gal A +/0 (a). This
observation is quantified in (c), comparing the number of axonal spheroids counted per field between α-Gal A +/0 and α-Gal A -/0 mice (n = 3).
Panels d and e are serial sections demonstrating axonal spheroids (white arrows, d) that are immunopositive for phosphorylated-α-synuclein
(white arrows, e) while panel (f) demonstrates the percentage of axonal spheroids that were positive for α-synuclein in serial sections (n = 3). Scale
bars = 50 microns.
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Figure 7 Phosphorylated α-synuclein lesions in the α-Gal A-deficient pons co-localize with ubiquitin and LC3. Sagittal brain sections from
male 20- to 24-month-old α-Gal A +/0 (a-d) or -/0 (b-l) mice were immunolabeled with antibodies against phosphorylated α-synuclein (a, e, i)
and ubiquitin (b, f) or LC3 (j). Colored arrowheads indicate large lesions containing phosphorylated α-synuclein, ubiquitin, or LC3, and arrows
indicate co-localization of large phosphorylated α-synuclein-containing lesions with either ubiquitin (h) or LC3 (l). Co-localization analysis was performed
using the thresholded Manders test. Manders co-localization between ubiquitin (M1) and phosphorylated-α-synuclein (M2) was calculated to be
(tM1 = 0.506 and tM2 = 0.856, Costes p-value = 1, n = 3), indicating strong co-localization of phosphorylated-α-synuclein signal with ubiquitin in the
pons of α-Gal A -/0 mice. Manders co-localization between phosphorylated-α-synuclein (M1) and LC3 (M2) was calculated to be (tM1 = 0.499 and
tM2 = 0.765, Costes p-value = 0.958, n = 3), indicating strong co-localization of LC3 signal with phosphorylated-α-synuclein in the pons of α-Gal
A -/0 mice. Scale bars = 50 microns.
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it will be useful in the future to assess levels of LC3-II by
western blot analysis in frozen brain specimens obtained
from α-Gal A-deficient versus wild-type mice, in addition
to determining the relative state of autophagic flux to
more accurately define the mechanisms by which α-Gal A
regulates macroautophagy and in turn the degradation of
autophagic substrate.
Although Fabry disease is considered first and fore-
most a vasculopathy by many investigators, our fin-
dings also demonstrate increases in parenchymal LC3
and LAMP-1 immunoreactivity localized to perinuclear
and neuritic regions of neurons (Figures 1 and 2). Thus
it is possible that ALP dysfunction in parenchymal tis-
sues resulting from α-Gal A deficiency either occursindependently to, or results in part from endothelial cell
dysfunction. Indeed, prominent findings of our study in-
clude enhanced endothelial cell immunoreactivity for
LAMP-1 (Figure 3) and cytoplasmic endothelial cell in-
clusions (Figure 4). As the specimens used for this ini-
tial report were from relatively old mice aged 20–
24 months of age, it will be interesting in future studies
to examine the course of the onset and progression of
vascular versus parenchymal pathology in the brains α-
Gal A-deficient mice.
Our findings of aberrant phosphorylated-α-synuclein
accumulation in α-Gal A-deficient mouse brain (Figures 5,
6 and 7) suggest that its metabolism relies on, at least in
part, functional α-Gal A. Previous studies have indicated
the importance of intact ALP function for the efficient
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models of lysosomal storage disorders [24,28-31,44-47].
Alpha-Gal A functions similarly to that of glucocerebrosi-
dase, a soluble lysosomal enzyme that is mutated in
Gaucher disease and is in the same sphingolipid cata-
bolism pathway [48]. Glucocerebrosidase deficiency was
shown recently to promote the accumulation of insoluble
α-synuclein species [28]. In addition, mutations in the hu-
man GBA gene are also a strong genetic risk factor for
Parkinson’s disease and glucocerebrosidase deficiency was
reported recently in brain tissue from patients with Par-
kinson’s disease [28,49,50]. Although a link between Fabry
disease and Parkinson’s disease has not been established, a
case report of Parkinsonism in Fabry disease has been
documented [51]. Alpha-Gal A deficiency has also been
reported in leukocytes from patients with sporadic Parkin-
son’s disease, suggesting that α-Gal A dysfunction may
regulate in part the pathogenesis of age-related neurode-
generative diseases like Parkinson’s, a possibility worthy of
future investigation [52-54].
Accumulation of Gb3 has been documented previously
in several tissues of α-Gal A-deficient mouse including the
brain [19,20]. Although ultrastructural analysis revealed
prominent accumulation of lipoprotein in α-Gal A-
deficient mouse brain, we were unable in the present
study to accurately assess levels of glycosphingolipids due
to the use of ethanol (which extracts lipids) to process
brain tissues [55]. It has been reported previously that
glucosylceramide, a glycosphingolipid that accumulates
following glucocerebrosidase deficiency not only can
promote the oligomerization of α-synuclein but can also
induce neurotoxicity when added exogenously to neur-
onal cultures [28,56]. These studies emphasize the im-
portance for future investigations of α-Gal A-deficiency
utilizing frozen brain tissue to accurately assess accu-
mulation of glycosphingolipids and their relative contri-
bution to the pathogenesis of Fabry-associated brain
disease.
The detection of axonal spheroids in the pons of α-
Gal A-deficient mouse brain (Figure 5) indicates axonal
degeneration, a novel finding for α-Gal A-deficient mice
and correlates with the previous observation in these
mice of reduced axonal number and size in peripheral
neurons [19]. CNS axonal spheroids were identified previ-
ously in other mouse models of lysosomal storage diseases
and suggest impairments in axonal transport [27,57,58]. In
addition, evidence of disrupted axonal transport was indi-
cated by the co-localization of phosphorylated-α-synuclein
immunoreactivity to axonal spheroids as shown previously
in other models [27,59]. Furthermore, the co-localization
of phosphorylated-α-synuclein-containing aggregates/sphe-
roids with ubiquitin and LC3 suggest the insoluble na-
ture of α-synuclein and alterations in the ALP that may
be causal for inducing axonal degeneration [36]. It isnot known at this time why the pons of α-Gal A deficient
mice was shown to be uniquely vulnerable to axonal de-
generation. Previous investigations have indicated a par-
ticular sensitivity of the hindbrain in Fabry patients to
vascular-associated ischemic attacks [5,7,60], thus the pos-
sibility exists for ischemic events to occur basally in α-Gal
A-deficient mice that are localized to this brain region.
Studies of peripheral nervous system function in α-Gal A
deficient mice have identified reduced motor neuron con-
duction velocity, alterations in locomotor activity, and
hypersensitivity to pain stimuli [19]. Whether alterations
in the peripheral nervous system are connected to our ob-
servations in the central nervous system remains unclear.
Future studies utilizing a rigorous stereological approach
will help to elucidate neuronal pathways/tracts in the pons
and other brain regions of α-Gal A-deficient mice that
contribute to this neurodegenerative phenotype.
Conclusion
In summary, our study reveals a consistent neuropatho-
logical and neurodegenerative phenotype existing in the
brains of aged α-Gal A-deficient mice that is intimately
associated with the disruption of the ALP. Future ana-
lysis of α-Gal A deficiency with respect to age, as well as
rigorous biochemical and stereological analysis of brain
specimens will all be useful in further delineating the on-
set and progression of CNS pathophysiology in these
mice.
Additional file
Additional file 1: Figure S1. Neuron count was not significantly
affected by α-Gal A deficiency. Sagittal brain sections from male 20- to
24-month-old α-Gal A +/0 (a-c) or -/0 (d-f) mice were immunolabeled
with an antibody against neuronal nuclei (NeuN). NeuN Positive cells
were counted from cortex, hippocampus, and pons, graphed (g), and
statistical analysis was performed with GraphPad Prism (n = 3).
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